Sharon Shacham

Co-Founder and Managing Director

2022 - Current

E44 Ventures supports visionary innovators in building and financing great companies that tackle humankind’s most critical climate challenges and better our planet for generations. By partnering with us, researchers, entrepreneurs, and corporations transform their brilliant ideas into commercial success. As Managing Partner at E44 Ventures, I'm passionate about investing in innovative climate technologies and exceptional talent to make a difference in the fight against global warming and make this world a better place to live in. I help forge strong collaborations with entrepreneurs, mentor building, and provide support across all investment stages. Our focus at E44 extends to global growth, unlocking opportunities in scientific, regulatory, and investor networks. Together, we drive commercial success and make a meaningful impact in the fight against global warming.

Advisory Board

2023

Phelas is advancing an innovative electricity storage system that harnesses solar and wind power, using a novel thermodynamic process to store energy in liquid air for a sustainable, continuous global renewable energy supply

Board Observer

2023

Gigablue merges science, AI, and nature to accelerate environmental balance, offering affordable, effective solutions for urgent, large-scale climate challenges. One planet, one last chance, one solution

Board Observer

2023

Carbonade’s innovative electrochemical system captures and converts CO2 into valuable products like fuel and plastics using renewable energy, aiding in the quest for net zero and climate change mitigation

Board Member

2023

Agripass is a robotic agritech company that is out to solve the world’s weeding problem. Creating a world-leader robotic weeding solution for conventional agriculture, Increasing yield, and reducing chemicals’ impact on health and environment

Founder

2009

Karyopharm (NASDAQ: KPTI) is a pioneering pharmaceutical company I founded in 2009. With our core technology leveraging the inhibition of nuclear export, we're dedicated to creating novel first-in-class drugs to treat cancer and other significant medical conditions. From a humble startup, Karyopharm has grown to boast over 400 employees across offices in the US, Germany, and Tel Aviv. I founded the Company in 2009 and grew the company from a start-up to>400 employees with offices in US, Germany and Tel Aviv. At Karyopharm I served as President and Chief Scientific Officer until 2021 and remain a member of its Scientific Advisory Board. Karyopharm created the novel oral cancer drug selinexor (Xpovio®) under my leadership and its development from idea to commercialization: Xpovio is now approved in US, EU, China, Israel, and other countries. I overseed the development plan of selinexor that included >25 Clinical Trials (Ph1-Ph3) and the submission of many INDs, 3 NDA, and 2 CTA submissions that led to the approval of Selinexor in US and EU.

Scientific Advisory Board Member

2009

Chief Scientific Officer

2021 - 2022

President and CSO

2011 - 2021

CEO and President

2009 - 2011

Scientific and Clinical Advisor

2021

Sporos Bioventures is a private biopharmaceutical company with a mission: to revolutionize the drug development process. We focus on key mechanisms and targets, aiming to expedite drug discovery research to early clinical-stage assets using a centralized infrastructure.

Board Member

2021

Acrivon Therapeutics, a clinical-stage oncology company, leveraging our unique precision medicine platform, Acrivon Predictive Precision Proteomics (AP3) to drive our drug pipeline. One of our leading programs is the advanced Phase 2 program, ACR-368 (prexasertib) – an active CHK1/2 inhibitor. We also have promising preclinical programs focusing on DNA Damage Response (DDR) and cell cycle regulation.

Board Member

2021

Scientific Advisor

2022

ProtAI is an Israeli AI-powered drug discovery startup that is revolutionizing the way new drugs can be discovered. ProtAI combines deep proteomics with machine learning to better combat complex diseases and create a healthier world.